Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa

马拉维和南非的艾滋病毒癌症筛查和预后创新，包括卡波西肉瘤、宫颈癌和淋巴瘤

• 批准号: 10238155
• 负责人: Carla J Chibwesha
• 金额: $ 110.9万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-13 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10238155
• 关键词: AIDS Malignancy Consortium; AIDS clinical trial group; AIDS related cancer; AIDS-Related Lymphoma; AIDS/HIV problem; Achievement; Acquired Immunodeficiency Syndrome; Address; Africa; Africa South of the Sahara; Basic Science; Biological Markers; Cancer Burden; Cancer Control; Cancer Prognosis; Caring; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communicable Diseases; Communities; Comprehensive Cancer Center; Crystallization; Data; Ensure; Epidemic; Flowers; Goals; HIV; Health; Hospitals; Individual; Infrastructure; Institutes; Institution; International; Kaposi Sarcoma; Knowledge; Leadership; Lymphoma; Malawi; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Medicine; Methods; Molecular; North Carolina; Patients; Persons; Policies; Population Sciences; Positioning Attribute; Principal Investigator; Prognosis; Recurrence; Research; Research Infrastructure; Research Personnel; Research Priority; Research Project Grants; Science; Site; South Africa; South African; Survival Rate; Training; Training Support; Training and Infrastructure; Translational Research; Trust; UNC Lineberger Comprehensive Cancer Center; United States National Institutes of Health; Universities; anticancer research; antiretroviral therapy; career; clinical research site; college; combat; comorbidity; data sharing; epidemiology study; global health; high risk; improved; innovation; insight; low and middle-income countries; next generation; oncology program; programs; response; screening; success; translational impact; tumor

ABSTRACT: OVERALL COMPONENT: Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa In response to RFA-CA-20-001, this application proposes to establish the UNC-Malawi-South Africa Cancer Consortium (UMSACC), to develop capacity and conduct high-impact research focused on HIV-associated cancers. The consortium builds on longstanding collaborations between the University of North Carolina at Chapel Hill, Lighthouse Trust in Malawi, Malawi Ministry of Health, Malawi College of Medicine, the University of the Witwatersrand, South Africa, and Stellenbosch University, South Africa. These partnerships have been made possible by leadership and participation in NIH networks conducting basic, clinical and epidemiologic research in the region. These existing relationships and robust infrastructure can now be leveraged for HIV- associated malignancies, which are overwhelming contributors to cancer burden in Malawi and South Africa even after widespread antiretroviral therapy usage. UMSACC is focused on the three most common HIV- associated cancers, Kaposi sarcoma (KS), cervical cancer, and lymphoma, and addresses the NIH HIV/AIDS research priorities by focusing on HIV-associated comorbidities which includes these AIDS-defining cancers. UMSACC proposes innovations for screening and prognosis of these cancers in persons living with HIV (PLWH) with the overall goal being to improve the health of PLWH. Our consortium will be led by principal investigators with highly complementary expertise using a team science approach. To support consortium objectives, a diverse team of investigators has been assembled spanning the clinical, population, and basic sciences, and includes Malawian, South African, and US scientific leaders. Moreover, a high priority is the training and support of junior investigators in the U.S. and Africa. The consortium will enhance existing administrative, operational, and research relationships between all partnering institutions and investigators. The External Advisory Board and Scientific Advisors will ensure that the consortium remains highly responsive to community needs in Malawi and South Africa, while also addressing urgent research questions facing the international HIV-associated cancer community. A focus of this consortium is to develop Malawi and South Africa to become international leaders in HIV- associated cancer research. Building on prior successes and partnerships outlined in this application, UMSACC is extremely well-positioned to catalyze a broad, coordinated, cancer control effort in Malawi and South Africa, and to advance the overall NCI scientific agenda for sub-Saharan Africa to reduce HIV- associated cancer burden in low- and middle-income countries.

摘要：整体组成部分：筛查和预后的创新艾滋病毒+癌症 包括卡波西肉瘤，宫颈癌和马拉维和南非的淋巴瘤 为了响应RFA-CA-20-001，该申请提议建立UNC-Malawi-South非洲癌症 财团（UMSACC），开发能力并进行高影响研究，重点是与HIV相关的 癌症。该财团建立在北卡罗来纳大学的长期合作基础上 马拉维医学院马拉维卫生部的马拉维灯塔信托教堂山，大学医学院 南非Witwatersrand和南非的Stellenbosch大学。这些伙伴关系已经 通过领导和参与进行基本，临床和流行病学的NIH网络使得成为可能 该地区的研究。这些现有的关系和牢固的基础设施现在可以利用艾滋病毒 相关的恶性肿瘤，这是马拉维和南非癌症负担的压倒性贡献者 即使在广泛的抗逆转录病毒治疗后也是如此。 UMSACC专注于三个最常见的HIV- 相关的癌症，Kaposi肉瘤（KS），宫颈癌和淋巴瘤，并解决了NIH HIV/AIDS 通过关注与艾滋病毒相关的合并症（包括这些定义艾滋病定义的癌症）的研究优先级。 UMSACC提出了这些癌症筛查和预后的创新 （PLWH）总体目标是改善PLWH的健康状况。 我们的财团将由具有高度互补专业知识的主要调查员使用团队科学领导 方法。为了支持联盟的目标，一支多样化的调查员团队已组建了 临床，人口和基础科学，包括马拉维，南非和美国科学领袖。 此外，优先考虑的是美国和非洲初级调查人员的培训和支持。这 财团将增强所有合作伙伴之间的现有行政，运营和研究关系 机构和调查人员。外部顾问委员会和科学顾问将确保 财团仍然对马拉维和南非的社区需求有很高的反应，同时也解决 紧急研究问题与国际艾滋病毒相关的癌症社区面临。 该财团的重点是发展马拉维和南非，成为艾滋病毒的国际领导人 相关的癌症研究。在此应用程序中概述的先前成功和伙伴关系的基础上， UMSACC的位置非常好，可以催化马拉维和 南非，并推进撒哈拉以南非洲的NCI总体科学议程，以减少艾滋病毒 低收入国家和中等收入国家的癌症负担。